The earnings call was predominantly positive with strong revenue growth, increased sales guidance, and robust market penetration for ARCALYST. However, some concerns remain about emerging competition and uncertainty around KPL-387's trial outcomes.

Company Guidance -

Q3 2025

During the Kiniksa Pharmaceutical Second Quarter 2025 Earnings Conference Call, the company raised its full-year 2025 net sales guidance for ARCALYST to between $625 million and $640 million, an increase from the prior range of $590 million to $605 million. This adjustment comes on the back of strong second-quarter performance, with ARCALYST generating $156.8 million in net revenue, marking a $19 million increase over the first quarter and a 52% year-over-year growth. The company also achieved a milestone of over $1 billion in cumulative net sales since the launch of ARCALYST. Additionally, patient compliance remained strong at over 85%, and payer approval rates exceeded 90%. Kiniksa continues to advance its pipeline, with the Phase II/III clinical trial of KPL-387 for recurrent pericarditis underway, expecting data in the second half of the next year.

Strong Revenue Growth for ARCALYST

ARCALYST generated net revenue of $156.8 million in the second quarter, representing a 52% year-over-year increase. The revenue growth led to an increase in net income to $17.8 million compared to a net loss of $3.9 million in the previous year.

Increased Sales Guidance for ARCALYST

Kiniksa raised its full-year 2025 ARCALYST net sales guidance to between $625 million and $640 million, up from the previous guidance of $590 million to $605 million.

Strong Market Penetration and Prescriber Growth

Penetration into the multiple recurrence population increased from approximately 13% at the end of last year to approximately 15% at the end of Q2. The number of prescribers increased significantly, with more than 325 additional healthcare professionals writing their first ARCALYST prescription in Q2.

Cash Flow Positive and Strong Balance Sheet

Kiniksa's cash balance increased by approximately $40 million to $307.8 million in the second quarter, supporting the company's operating plan to remain cash flow positive on an annual basis.

Kiniksa Pharmaceuticals (KNSA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KNSA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.31 / -	-0.18	―	―	―
Jul 29, 2025	2025 (Q2)	0.22 / 0.23	-0.06	483.33% (+0.29)
Apr 29, 2025	2025 (Q1)	0.13 / 0.11	-0.25	144.00% (+0.36)
Feb 25, 2025	2024 (Q4)	0.02 / -0.12	0.35	-134.29% (-0.47)
Oct 29, 2024	2024 (Q3)	0.02 / -0.18	-0.2	10.00% (+0.02)
Jul 23, 2024	2024 (Q2)	-0.08 / -0.06	0.21	-128.57% (-0.27)
Apr 23, 2024	2024 (Q1)	-0.08 / -0.25	-0.18	-38.89% (-0.07)
Feb 28, 2024	2023 (Q4)	-0.10 / 0.35	0.06	483.33% (+0.29)
Oct 31, 2023	2023 (Q3)	-0.17 / -0.20	3.23	-106.19% (-3.43)
Jul 25, 2023	2023 (Q2)	-0.14 / 0.21	-0.29	172.41% (+0.50)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KNSA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$27.04	$30.37	+12.32%
Apr 29, 2025	$21.47	$25.88	+20.54%
Feb 25, 2025	$19.63	$19.72	+0.46%
Oct 29, 2024	$27.59	$23.26	-15.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kiniksa Pharmaceuticals (KNSA) report earnings?

Kiniksa Pharmaceuticals (KNSA) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Kiniksa Pharmaceuticals (KNSA) earnings time?

Kiniksa Pharmaceuticals (KNSA) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KNSA EPS forecast?

KNSA EPS forecast for the fiscal quarter 2025 (Q3) is 0.31.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing